$3.33▾ 2.06%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Recursion Pharmaceuticals, Inc. - Class A Common Stock's earnings-quality signal is not available yet.
Key numbers
Recent news
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider
The Market Just Told You Which Layer Of AI Biology It Is Paying For
AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players